News Highlights: Top Company News of the Day - Tuesday at 11 AM ET
23 January 2024 - 4:15PM
Dow Jones News
Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe
The agreement in principle addresses an investigation brought by
more than 40 states into the marketing of its talcum-based baby
powder.
Verizon's stock rockets as earnings bring a big wireless surprise
Verizon saw its best performance in four years on one metric
tracking consumer wireless account growth.
P&G Earnings Show Some Consumers Are Getting Used to Higher Prices
The consumer-products giant said that sales volume increased for
categories including hair care and family care in the latest
quarter.
3M's stock suffering biggest selloff in 5 years after 2024 profit warning
3M's stock tanked Tuesday, after the consumer, industrial and
healthcare-products company provided a 2024 profit outlook that was
well below forecasts, which overshadowed fourth-quarter results
that topped expectations.
GE's stock drops after downbeat outlook for last full quarter before breakup
The aerospace, power and renewable energy company's
disappointing profit outlook for the current overshadowed a
fourth-quarter earnings beat that was fueled by strength in the GE
Vernova businesses.
Netflix to Pay $5 Billion for 'WWE Raw' Rights in Live Events Push
The multiyear deal will give the streaming giant exclusive
rights to the hit wrestling show in the U.S. as well as
international distribution rights in several countries.
Amazon Fined in France Over Alleged Employee Surveillance
France's privacy watchdog fined Amazon.com's local warehouse
management business, saying the company had put in place an
"excessively intrusive" system to keep track of staff
performance.
Microsoft Balances SEC Disclosure Rules After Email Hack
Ongoing investigation finds no signs yet of material impact,
company says.
Why It Makes Sense for New EV Drivers to Look Beyond Tesla
The brand is pursuing a different approach to making its
vehicles more affordable-and it's at the expense of existing Tesla
owners.
Sanofi to Buy Rare-Disease Assets From Inhibrx
Sanofi plans to buy assets from U.S. biopharmaceutical company
Inhibrx in a deal valued at up to $2.2 billion.
(END) Dow Jones Newswires
January 23, 2024 11:00 ET (16:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.